Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection
Key facts
- Who runs it
- University of Mississippi Medical Center
- Where
- Jackson, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 492 people enrolled
- Started
- 1 Jul 2022
- Ended
- 8 Dec 2025
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Immulina TM
- Placebo
- Record updated
- 30 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Ages 18-59 (study group 1) or ages 65 and above (study group 2)
- Any chronic illness must be determined (by PI team) to be stable as evidenced by no changes in medical regimens within 30 days of enrollment
- Ability to comprehend the specific activities required to participate in the trial for which the participant is to be enrolled
Who cannot take part
- Active autoimmune diseases regardless of clinical stability. A history of autoimmune disease that is not considered active (i.e. no medical therapy for at least 1 year prior to enrollment) will not be excluded
- Any acute illness or significant injury within 30 days of enrollment
- Specific disease entities, which, in the opinion of the PI, could reasonably be assumed to have dysfunctional immune function as a component of their illness. These include HIV, AIDS, uncontrolled asthma, uncontrolled eczema, uncontrolled allergic rhinitis, uncontrolled urticaria, Rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, Type-1 diabetes mellitus, Guillain-Barr syndrome, Grave's disease, Hashimoto's thyroiditis, myasthenia gravis or vasculitis
- History of unstable chronic illness within 30 days of enrollment
- Unable/unwilling to commit to multiple research clinic visits which will be described in detail
Where in United States
- University of Mississippi Medical CenterJackson, United States
About the trial
What the trial wants to find out
This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.
The 4 groups in the trial
- PlaceboPlacebo, for comparison
inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 16 weeks duration.
- Immulina TM 200 mg/dayTreatment being tested
Immulina Dietary supplementation (200 mg per capsule); 1-200 mg capsule and 1 placebo capsule given by mouth in the morning and 2 placebo capsules given by mouth in the evening for 16 weeks duration.
Treatment: Immulina TM
- Immulina TM 400 mg/dayTreatment being tested
Immulina Dietary supplementation (200 mg per capsule); 1-200 mg capsule and 1 placebo capsule given by mouth in the morning and 1-200 mg capsule and 1 placebo capsule given by mouth in the evening for 16 weeks duration.
Treatment: Immulina TM
- Immulina TM 800 mg/dayTreatment being tested
Immulina Dietary supplementation (200 mg per capsule); 2-200 mg capsules given by mouth in the morning and 2-200 mg capsules given by mouth in the evening for 16 weeks duration.
Treatment: Immulina TM
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Oral Immulina TM on Natural Killer Cell Activities and Other Biomarkers Associated With Increasing Host Immune Resilience to Upper Respiratory Viruses in Normal Human Volunteers
- Record updated
- 30 July 2026